The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease

  • Lars Holger Ehlers (Novo Nordisk Foundation) (Creator)
  • Mark Lamotte (Creator)
  • Sofia Monteiro (Creator)
  • Susanne Sandgaard (Creator)
  • Pia Holmgaard (Creator)
  • Evan C. Frary (Creator)
  • Niels Ejskjær (Creator)

Dataset

Description

Article full text The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite). © The authors, CC-BY-NC 2021.
Date made available26 Mar 2021
PublisherAdis Journals

Access Dataset

  • 1 Journal article

Cite this